Table 1.
Recommended adult dose schedules for HepA, HepB2, HepB3 and HepAB.
Fig 1.
Patient identification flowchart.
*Study period for HepA: 1/01/2011 to 6/30/2020; HepB2: 11/7/2017 to 6/30/2020; HepB3 and HepAB: 1/01/2011 to 06/30/2020. Note: HepB2 became available in the U.S. on 11/7/2017.
Table 2.
Socio-demographic and clinical characteristics of vaccine recipients (by vaccine series type).
Table 3.
Proportion of individuals who completed the vaccine series at 6, 12, 18 and 24 months after first dose.
Fig 2.
Cumulative proportion of individuals who completed the vaccine series, by time (in days) since first dose, for: (a) HepA (b) HepB2 (c) HepB3 (d) HepAB.
Table 4.
Adherence rates among US adults who initiate vaccination for Hepatitis A or B.
Fig 3.
Impact of sociodemographic and clinical/behavioral variables on adherence to Hepatitis A and B vaccine schedules (a) Age (b) Race (c) Income (d) CCI score (e) Gender (f) Education. CCI: Charlson Comorbidity Index; CI: Confidence Interval. Right side of the dashed line indicates greater odds of adherence vs the reference subgroup.